SecBot SecBot
PRESS-RELEASE ·Filed May 11, 2026

DRTS

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The complete responses in 2/3 patients are a strong early signal in a notoriously difficult-to-treat cancer. Monitor the conference call at 8:30am ET for additional patient details and timeline for FDA feedback on trial continuation. The stock could see significant upside if the data is viewed as de-risking the platform, but the small sample size (n=3) warrants caution, watch for any adverse safety signals or FDA delays.

DirectionBullish
Confidencemedium
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.34
T+0 close · May 11, 2026 · via day close
Latest settled
+28.24%
T+60 · $13.26
Vs SPY
+23.85%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $10.34entry
  2. T+1 · 6mo ago −4.45%α −4.31% · $9.88
  3. T+5 · 6mo ago −3.00%α −2.91% · $10.03
  4. T+20 · 5mo ago −11.12%α −10.82% · $9.19
  5. T+60 · 3mo ago +28.24%α +23.85% · $13.26
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau reported groundbreaking interim data from its REGAIN trial for recurrent glioblastoma, showing complete responses in 2 of the first 3 patients with total disappearance of tumor lesions. The data is early (n=3) but highly promising in a devastating disease with few effective treatments, supporting the company's core strategy and potential FDA advancement.

Key Facts

  • First 2 of 3 patients demonstrated complete response (total disappearance of all enhancing tumor lesions) per RANO criteria
  • Third patient showed stable disease with 30% decrease in tumor dimension
  • No local or distant recurrence in any patient as of May 3, 2026 cutoff
  • One grade 3 SAE (seizure with temporary paralysis) observed, which resolved with steroids
  • Trial expected to enroll up to 10 US patients with recurrent GBM not amenable to surgical resection
  • FDA requested interim safety analysis; company awaiting FDA confirmation to continue enrollment
  • Glioblastoma has ~14,000 new US cases/year, median survival ~8 months, 5-year survival <10%

Financial Impact

No financial figures disclosed; potential multi-billion dollar market opportunity if Alpha DaRT gains approval for GBM and other brain cancers

revenuemarket cap

Risk Factors

  • Very small sample size (n=3), early data may not replicate in larger cohort
  • FDA may require additional safety data or halt enrollment
  • Competing therapies (antiangiogenics, checkpoint inhibitors) could limit market adoption
  • Company has limited operating history and needs additional funding for commercialization

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3291734

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026